Dr. Melissa A Reimers, M.D.
Claim this profileWashington University School of Medicine
Expert in Parotid Gland Cancer
Studies Kidney Cancer
16 reported clinical trials
25 drugs studied
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
TFE-3/B translocation positive
2Kidney Cancer
Stage IV
Stage III
TFE-3/B translocation positive
Affiliated Hospitals
Clinical Trials Melissa A Reimers, M.D. is currently running
Cabozantinib +/− Atezolizumab
for Advanced Kidney Cancer
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread from where it first started (primary site) to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look like long, thin finger-like growths under a microscope. It is also called papillary kidney cancer or PRCC. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the tumor and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply and may also prevent the growth of new blood vessels that tumors need to grow. By these actions it may help slow or stop the spread of tumor cells. Combination therapy with atezolizumab and cabozantinib may shrink the tumor and allow a longer survival time in patients with metastatic renal cell carcinoma.
Recruiting1 award Phase 230 criteria
Personalized Cancer Vaccine
for Bladder Cancer
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Recruiting1 award Phase 17 criteria
More about Melissa A Reimers, M.D.
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Melissa A Reimers, M.D. has experience with
- Nivolumab
- Cabozantinib
- Pembrolizumab
- Atezolizumab
- Ipilimumab
- Avelumab
Breakdown of trials Melissa A Reimers, M.D. has run
Parotid Gland Cancer
Kidney Cancer
Renal Cell Carcinoma
Bladder Cancer
Prostatic Neoplasm
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Melissa A Reimers, M.D. specialize in?
Is Melissa A Reimers, M.D. currently recruiting for clinical trials?
Are there any treatments that Melissa A Reimers, M.D. has studied deeply?
What is the best way to schedule an appointment with Melissa A Reimers, M.D.?
What is the office address of Melissa A Reimers, M.D.?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.